HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
HUTCHMED to Announce 2026 Half-Year Financial Results
Buy These 3 HCM Software Solution Stocks to Tap Short-Term Potential
Syndio Acquires Embrace.ai
isolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to Anthropic's Claude Connectors Directory
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees
Paychex Recognized as a Top WorkTech Company by TIME
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
U.S. Office of Personnel Management Selects Oracle to Power Federal Workforce Modernization
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms
Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) PT at $16.88
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
Paycom Receives HCM Technology Signal Award for Workforce Change
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
HUTCHMED H2 Earnings Call Highlights
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript
Workday Faces Pressure as FY27 Guidance Highlights Slower Growth
HUTCHMED (China) Limited Sponsored ADR $HCM Shares Sold by M&G PLC
HCM IV Acquisition Corp Announces Pricing of $250 Million Initial Public Offering
3 HCM Stocks to Consider After January's Strong U.S. Jobs Report
HUTCHMED to Announce 2025 Final Results
HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume – Here’s Why
Homeland Provides Clarification on Prior Investor Relations Services Agreement with HoldCo Markets
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Recommendation of “Hold” by Analysts
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know
Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Target Price at $20.88
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript